(Q45353010)

13 December 2017

title

Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology (English)

1 reference

13 December 2017

1 reference

1 reference

Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology

series ordinal

1

1 reference

13 December 2017

publication date

1 January 2013

1 reference

13 December 2017

1 reference

13 December 2017

volume

43

1 reference

13 December 2017

issue

1

1 reference

13 December 2017

page(s)

1-34

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Clinical Pharmacokinetics of Interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Administration of interferon at night may increase its therapeutic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

The interferon response circuit: induction and suppression by pathogenic viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

21 January 2018

Viruses and interferons

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

How cells respond to interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Neuropsychiatric adverse effects of interferon-alpha: recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

The neuroimmunology of stress and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α-fetoprotein levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Long-term course of interferon-treated chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Long-term follow-up study of sustained biochemical responders with interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Ribavirin treatment for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

The association between hepatitis C infection and survival after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Treating hepatitis C infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Treatment of chronic hepatitis C virus infection with pegylated interferon and ribavirin in cirrhotic patients awaiting liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Efficacy of Stronger Neo-Minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

The long term efficacy of glycyrrhizin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Glycyrrhizin injection therapy prevents hepatocellular carcinogenesis in patients with interferon-resistant active chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

Efficacy and safety of addition of minor bloodletting (petit phlebotomy) in hepatitis C virus-infected patients receiving regular glycyrrhizin injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12020

21 January 2018

Identifiers

DOI

10.1111/HEPR.12020

1 reference

13 December 2017

1 reference